Brian W Pugh, DO | |
6028 S Ridgeline Dr, Ste 201, Ogden, UT 84405-6914 | |
(801) 475-5400 | |
(801) 475-8614 |
Full Name | Brian W Pugh |
---|---|
Gender | Male |
Speciality | Internal Medicine - Gastroenterology |
Location | 6028 S Ridgeline Dr, Ogden, Utah |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023005808 | NPI | - | NPPES |
2900043 | Other | UNITED HEALTHCARE | |
870653164002 | Medicaid | UT | |
107008467101 | Other | IHC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | 3619881204 (Utah) | Primary |
Entity Name | Tanner Memorial Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447239355 PECOS PAC ID: 4284547985 Enrollment ID: O20031110000132 |
News Archive
Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.
Analysts predict the poverty rate will decline by up to half a percentage point from its current level of 15 percent, or 46.2 million people.
As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.
A significant advance in the understanding of a childhood cancer called Neuroblastoma has been made by scientists from the Smurfit Institute of Genetics at Trinity College Dublin.
Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Brian W Pugh, DO 6028 S Ridgeline Dr, Ste 201, Ogden, UT 84405-6914 Ph: (801) 475-5400 | Brian W Pugh, DO 6028 S Ridgeline Dr, Ste 201, Ogden, UT 84405-6914 Ph: (801) 475-5400 |
News Archive
Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.
Analysts predict the poverty rate will decline by up to half a percentage point from its current level of 15 percent, or 46.2 million people.
As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.
A significant advance in the understanding of a childhood cancer called Neuroblastoma has been made by scientists from the Smurfit Institute of Genetics at Trinity College Dublin.
Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.
› Verified 5 days ago
Ewa Gniado, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 Fax: 801-387-7910 | |
Jaclyn Nguyen, Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 | |
Dr. Timothy Trask, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4401 Harrison Blvd, Ogden, UT 84403 Phone: 801-387-3654 | |
Gregory T Almony, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5405 S 500 E, Suite #204, Ogden, UT 84405 Phone: 801-479-0194 Fax: 801-479-5642 | |
Dr. Jack D Wahlen, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Ste 3630, Ogden, UT 84403 Phone: 801-387-7900 Fax: 801-387-7910 | |
Gary K Goucher, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, #3815, Ogden, UT 84403 Phone: 801-387-2575 Fax: 801-387-2585 |